Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists

Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Refinement of intermediate-risk Karyotypes according to the IPSS-R in patients with myelodysplastic neoplasms (MDS).

Annals of hematology·2025

Same author

Allogeneic Hematopoietic Stem Cell Transplantation in Refractory Multiple Myeloma-A Retrospective Multicenter Analysis.

European journal of haematology·2024

Same author

The new WHO 2022 and ICC proposals for the classification of myelodysplastic neoplasms. Validation based on the Düsseldorf MDS Registry and proposals for a merged classification.

Leukemia·2024

Same author

<i>"Activity Matters was great - I now realize: if I move, I'm fitter.":</i> development and process evaluation of a web-based program for persons with multiple sclerosis.

Disability and rehabilitation·2023

Same author

Unique [<sup>18</sup>F]FDG PET imaging pattern of drug-induced acute generalized exanthematous pustulosis within the SCAR-spectrum.

European journal of nuclear medicine and molecular imaging·2022

Same author

Therapy-related myeloid neoplasms following treatment for multiple myeloma-a single center analysis.

Annals of hematology·2022

Search research articles

Related Experiment Video

Updated: Jun 16, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Bendamustine in patients with relapsed or refractory multiple myeloma.

M Michael¹, I Bruns, E Bölke

¹Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine-University, Duesseldorf, Germany.

European Journal of Medical Research

|February 18, 2010

Summary

Bendamustine shows effectiveness as salvage therapy for advanced multiple myeloma patients, with mild toxicity. Further clinical trials are recommended to explore its role in managing this complex condition.

Related Experiment Videos

Last Updated: Jun 16, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

Hematology
Oncology
Clinical Pharmacology

Background:

Bendamustine is an established effective therapy for early-line multiple myeloma.
Limited data exists regarding bendamustine's efficacy in advanced or refractory multiple myeloma cases.

Purpose of the Study:

To evaluate the effectiveness and safety of bendamustine as salvage therapy in patients with relapsed or refractory multiple myeloma.
To determine response rates, event-free survival, and overall survival in this patient population.

Main Methods:

Retrospective analysis of 39 patients with relapsed/refractory multiple myeloma treated with bendamustine salvage therapy.
Patients received a median of 3 cycles of bendamustine (80-150 mg/m² on days 1+2) after a median of 2 prior therapies.
Bendamustine was administered as monotherapy in 39% and with steroids in 61% of patients.

Main Results:

Mild to moderate toxicity was observed.
Overall response rates included 3% very good partial response (vgPR), 33% partial response (PR), 18% minimal response (MR), and 26% stable disease (SD).
Median event-free survival was 7 months, and median overall survival was 17 months.

Conclusions:

Bendamustine demonstrates efficacy and acceptable toxicity in advanced multiple myeloma patients undergoing salvage therapy.
The findings support further investigation of bendamustine in clinical trials for advanced multiple myeloma.